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Abstract
Introduction of the National Institute of Mental Health’s Research Domain Criteria and revision of 
diagnostic classification for Autism Spectrum Disorder in the latest diagnostic manual call for a 
new way of conceptualizing heterogeneous ASD features. We propose a novel conceptualization 
of ASD, borrowing from the schizophrenia literature in clustering ASD features along positive, 
negative, and cognitive dimensions. We argue that this dimensional conceptualization can offer 
improved ability to classify, diagnose, and treat, to apply and predict response to treatment, and to 
explore underlying neural and genetic alterations that may contribute to particular feature clusters. 
We suggest the proposed conceptualization can advance the field in a manner that may prove 
clinically and biologically useful for understanding and addressing heterogeneity within ASD.
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The introduction of the National Institute of Mental Health (NIMH)’s Research Domain 
Criteria (RDoC) initiative, in conjunction with the recently revised diagnostic classification 
of a broad Autism Spectrum Disorder (ASD) category, calls for novel ways of 
conceptualizing and clustering heterogeneity among ASD features. In this paper, we borrow 
from the schizophrenia literature in proposing a conceptualization of ASD on the basis of 
positive, negative, and cognitive features. We propose that this novel dimensional 
conceptualization may be informative for researchers and clinicians alike, offering: (1) a new 
lens on viewing symptomatology that could better capture heterogeneity, improve diagnostic 
precision, and allow more targeted consideration of dimensional symptom overlap with other 
disorders; (2) an opportunity to apply treatment approaches best suited to the dimensional 
disturbances evident in a given individual; and (3) a new perspective from which to explore 
underlying disruptions in neural and genetic pathways that may contribute to particular 
clusters of symptoms or features. In so doing, the proposed conceptualization attempts to 
move the field of ASD research forward in a manner that may prove clinically and 
biologically useful for contending with heterogeneity within the autism spectrum.
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The Fifth Edition of the Diagnostic and Statistical Manual (DSM-5) refined diagnostic 
criteria and classification for autism spectrum disorder (ASD), moving from related 
subdiagnoses to a single, spectrum diagnosis (APA 2013). This change reflected the limited 
validity and reliability of DSM-IV diagnostic categories (Mahjouri and Lord 2012; Volkmar 
and McPartland 2014). For example, clinician, clinic location, IQ, age, and comorbid 
symptoms predicted DSM-IV diagnosis better than did the core features differentiating 
among them in the diagnostic rubric (Lord et al. 2012). The clinical relevance of former 
subcategories was also challenged, with treatment selection and response reflecting specific 
features (e.g., language delays), comorbidities (e.g., hyperactivity, anxiety), and 
developmental and cognitive level, rather than particular diagnosis (Happe 2011). The shift 
to a new, broader ASD category in the DSM-5 was intended to conceptualize the disorder at 
a level that more accurately corresponds to clinical correlates and the existing state of 
limited scientific knowledge regarding valid, replicable subtypes, while simultaneously 
opening new freedom for exploring novel ways to parse heterogeneity (Grzadzinski et al. 
2013).
Though ASD is now conceptualized as an umbrella category, it is widely acknowledged that 
ASD is not a single biological entity (Geschwind and Levitt 2007; Happe et al. 2006). 
Instead, ASD likely reflects a ‘dimensional’ disturbance (Happe et al. 2006; Insel et al. 
2010), with great phenotypic heterogeneity (e.g., in spoken language and social interest) that 
represents extreme values on multiple functional continua that extend into the normative 
range. Efforts to parse this heterogeneity have focused on both feature expression 
(Willemsen-Swinkels and Buitelaar 2002) and neural and genetic mechanisms underlying 
distinct phenotypic dimensions (Jeste and Geschwind 2014). Nevertheless, despite 
promising advances (e.g., specific genetic subtypes; Bernier et al. 2014), the field as yet has 
failed to characterize subtypes in ways that (a) are biologically and prognostically 
meaningful and reliable, and (b) explain the range of phenotypic expression. This goal is 
critical for the identification of etiological mechanisms and development of individualized 
treatment strategies. Novel ways of conceptualizing feature clusters may be helpful in 
driving research to better understand the etiology of various phenotypic presentations of 
ASD. Here we propose that development of a dimensional understanding of ASD may 
benefit from insights derived in the context of clinical research in schizophrenia.
Symptom Dimensions in Schizophrenia—Defining an Illness Spectrum
Schizophrenia shares a long history with ASD (Ornitz 1969) and, prior to 1980, autism was 
considered a subtype of early-emerging schizophrenia (APA 1968). Like ASD, 
schizophrenia is a heterogeneous clinical syndrome characterized by a diverse array of signs 
and symptoms that exhibit a highly variable presentation across patients (Jablensky 2006; 
Tamminga and Holcomb 2005). While there are ‘canonical’ symptoms of the illness, such as 
disturbances in belief (delusions) and perception (hallucinations), no one sign or symptom is 
sufficient to establish a formal schizophrenia diagnosis. Like ASD (Happe et al. 2006), 
schizophrenia is conceptualized as a group of disorders, or “schizophrenias” (Bleuler 1950; 
Siever et al. 1993), varying across symptom dimensions (Barch et al. 2013). In line with this 
view, as with ASD, in the transition to the DSM-5, schizophrenia subtypes (e.g., 
disorganized, paranoid, catatonic) were removed due to their having limited reliability for 
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parsing heterogeneity (Linscott and van Os 2010), as well as limited utility for informing 
treatment or predicting course of illness (Tandon 2012; Tandon et al. 2013).
Although reliable subtypes for schizophrenia have not been validated, subsets of 
schizophrenia characteristics have been effectively parsed in terms of “positive” versus 
“negative” symptoms (N. C. Andreasen and Olsen 1982) that occur alongside reliable 
patterns of cognitive deficits (Barch 2005; Reichenberg et al. 2009). Positive symptoms of 
schizophrenia include hallucinations, delusions, and bizarre and disorganized speech and 
behaviors—characteristics that are absent in typical adults. Negative symptoms, in contrast, 
are those that represent a deficit of function, or a lack of behaviors that are normally present 
in typical adults. In schizophrenia, these features include blunted affect, anhedonia, 
avolition, and alogia. Finally, cognitive deficits in schizophrenia are quite diffuse and 
include impairments in processing speed, problem solving and reasoning, verbal and non-
verbal learning and memory, attention, working memory, and executive functioning 
(Fatouros-Bergman et al. 2014; Nuechterlein et al. 2004).
Classifying schizophrenia symptoms along positive, negative, and cognitive dimensions has 
not been important just with regard to nosology and classification. Rather, this 
conceptualization has led to improved ability to diagnose and treat, to predict and track 
course of illness, response to treatment, and functional outcomes in affected patients (Chen 
et al. 2013; Mohr et al. 2004), and to begin to understand the universality versus specificity 
of underlying neural abnormalities and genetic alterations in driving clusters of symptoms 
within and across individuals (Barch and Ceaser 2012). Positive symptoms are often more 
acute and transient and respond most reliably to anti-psychotic medications (Angrist et al. 
1980; Chien and Yip 2013; Leucht et al. 2009). Negative symptoms, on the other hand, are 
more stable, are associated with worse premorbid functioning as well as poorer psychosocial 
adjustment and functional outcomes (Rabinowitz et al. 2012), and have only recently been 
more effectively targeted by interventions (Brunelin et al. 2012; Goff et al. 2001a, b; 
Levkovitz et al. 2010). Finally, cognitive features are unique in preceding onset of acute 
illness (Bora and Murray 2014), are most treatment refractory (Harvey and Keefe 2001), and 
have led to organized, NIMH-funded efforts in the research community to assess and 
develop interventions particularly targeting this dimension (Marder 2011). With regard to 
underlying genetics and neurobiology, while many have proposed common pathways and 
neural abnormalities in schizophrenia (Coyle 2006; Krystal et al. 2003; Uhlhaas and Singer 
2010), it is also likely there are at least some more specific or localized differences in brain 
development and functioning driving subsets of abnormalities associated with this disorder 
(Lisman 2012). To this end, the schizophrenia research community has found it fruitful to 
consider symptom dimensions in understanding pathways and circuitry by which underlying 
mechanisms lead to specific disease manifestations.
Application to Autism Spectrum Disorder
We propose that considering symptoms of ASD along positive, negative, and cognitive 
dimensions may represent a meaningful strategy for parsing heterogeneity, paralleling the 
work that has been done in schizophrenia. We do not intend to suggest that positive and 
negative dimensions of ASD are the same as those in schizophrenia, but rather that 
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conceptualizing existing features of ASD as those that are atypical (not present in typical 
development, but present in ASD), deficient (those that are present in typical development, 
but delayed, deficient, or absent in ASD), or cognitively-driven may open new avenues for 
scientific discourse, research, and clinical practice. In this framework, positive features of 
ASD include behaviors that are not often seen in typical individuals, such as stereotypic 
motor behaviors, echolalia, and circumscribed interests. In contrast, negative features reflect 
the absence of behaviors expected in typical individuals, and include reduction in eye 
contact, facial expression, social engagement, and spoken language. Finally, the cognitive 
dimension could include patterns of thinking, behavior, and relating that are most clearly 
cognitively-driven and common among individuals with ASD, such as rigidity of thinking, 
deficits with set shifting and broader executive functioning, impaired theory of mind, and 
commonly detected neuropsychological deficits (e.g., in processing speed, verbal IQ, 
working memory, episodic memory, sustained attention) (Brunsdon and Happé 2014). Table 
1 reflects additional examples of framing hallmark ASD features, as currently represented in 
the DSM-5 rubric, along positive, negative, and cognitive dimensions. In the paragraphs that 
follow, we demonstrate how clustering ASD features in this manner can be an informative 
conceptual framework for making diagnostic distinctions, applying treatments, and 
understanding etiology.
Existing knowledge of ASD phenotypic profiles and developmental course points to the 
possibility that conceptualizing features along positive, negative, and cognitive dimensions 
could have utility with regard to diagnosis and prognosis. For example, in toddlers, the 
presence of positive motor stereotypy behaviors does not differentiate children with ASD 
from those with typical development or developmental delay (Baranek 1999; Lord 1995), as 
many of these behaviors are normative at this young age. As such, negative signs, 
characterized by the absence or delay in development of more typical social behaviors (e.g., 
response to name) are the best predictors of ASD diagnosis in young children (Barton et al. 
2012).
At later ages, the persistence and emergence of positive signs may be more diagnostic, as 
some positive features, such as circumscribed interests, become more pronounced and 
impairing at older ages (South et al. 2005). Similarly, with age, stereotypies increasingly 
differentiate ASD from typical development (MacDonald et al. 2007). On the other hand, 
negative features, while fairly diagnostic in young children with ASD, increasingly overlap 
with other disorders in later childhood and adolescence, leading to challenges in differential 
diagnosis in individuals with exclusively negative symptoms. For example, symptoms of 
anxiety, depression, and schizophrenia (e.g., blunted affect, reduced eye contact, social 
isolation or avoidance; Blanchard and Cohen 2006) overlap with ASD negative features, 
making this cluster of features less helpful for differential diagnosis in older children, 
adolescents, and adults. Thus, when older children are presenting for a first time diagnosis 
with a question of ASD and display primarily negative features within the proposed 
framework, it may be important to consider whether their presentation is better explained by 
an alternative primary diagnosis, particularly if no positive features of ASD have ever been 
present. On the other hand, when an older child with a past diagnosis of ASD displays both 
positive and negative features of ASD but negative features have become increasingly 
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prominent with age, clinicians should continue to consider whether a comorbid anxiety or 
mood disorder is occurring alongside the primary ASD diagnosis.
Finally, though perhaps least specific to ASD versus other neurodevelopmental disorders, 
common cognitive styles and features can often lead to specific patterns of behaviors that 
cause significant functional impairment for individuals with ASD when navigating 
educational, social, domestic, and vocational challenges. As such, cognitive features may 
underlie significant behavioral challenges and require intervention for subsets of patients, 
thus warranting intentional attention to salient features along this dimension. As a guiding 
principle, we suggest that clinicians could benefit from considering ASD features along our 
proposed dimensions in making their initial diagnosis, in considering what alternative 
diagnoses might better explain the individual’s presentation and/or what comorbidity the 
patient might currently be experiencing, in forecasting which future behaviors or difficulties 
a child might be at more or less at risk for, and in considering which treatment approaches to 
recommend. Thus, we believe that this framework could be quite helpful for improving 
current diagnostic thinking and practices.
At present, existing assessment measures for ASD do not lend themselves to conceptualizing 
relevant features along positive, negative, and cognitive dimensions. As most were derived to 
match DSM categories (social, communication, repetitive behaviors) in their existing format 
and with their existing scales, these measures offer little support for clinicians or researchers 
wishing to conceptualize features along our proposed dimensions. On some scales, it may be 
possible to derive positive, negative, and cognitive factors for existing subsets of items that 
have not previously been grouped together. On other measures, however, existing items lump 
both positive and negative expressions of a given feature (e.g., a single item for inappropriate 
affect, which does not differentiate exaggerated from flat affect), and additional measure 
development and refinement would be necessary. In schizophrenia, the most widely used 
rating scales (i.e., Positive and Negative Syndrome Scale, Scale for the Assessment of 
Negative Symptoms, Scale for the Assessment of Positive Symptoms; Andreasen 1984, 
1989; Kay et al. 1987) divide features along positive and negative dimensions, which has 
been useful in the clinical context for characterizing an individual’s diagnostic presentation 
and for measuring the response of subsets of features to treatment. In research, these 
dimensional rating scales have been useful for measuring efficacy in clinical trials as well as 
for evaluating onto which aspects of the clinical phenotype particular behavioral or 
neurological findings map. Given the utility of these dimensional measures in schizophrenia, 
it may be worthwhile for the autism community to consider whether development of 
analogous scales for ASD would be a fruitful investment.
Similarly, the DSM-5 rubric for ASD diagnosis includes only severity ratings for social 
communication and restricted/repetitive behaviors, whereas for schizophrenia, an optional 
severity rating scale (the “Clinician-Rated Dimensions of Psychosis Symptom Severity”) is 
available for rating various positive, negative, and cognitive features in patients with this 
disorder (APA 2013). In line with our proposal, it may be meaningful to develop a parallel 
optional rating scale for the positive, negative, and cognitive features of ASD in order 
provide a richer clinical picture of the patient’s functioning and to inform treatment 
planning. Such severity ratings could be useful for capturing the most prominent features 
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affecting an individual at a given point in time, as the relative expression and impact of 
features along dimensions will certainly vary both across individuals as well as within 
individuals over the course of development, as settings change, and as treatments yield 
effects.
Consideration of existing interventions suggests that many may be differentially useful for 
treating positive, negative, and cognitive features of ASD, though they have not previously 
been conceptualized or applied within this framework. For example, some medications are 
effective in treating stereotyped behaviors (a positive feature; McPheeters et al. 2011), 
whereas other novel approaches, such as oxytocin, aim to increase social approach (decrease 
a negative feature; Andari et al. 2010). Likewise, different behavioral interventions may be 
indicated for positive versus negative features. Whereas extinction procedures may be used 
to eliminate undesirable or atypical behaviors (positive features; Wolff et al. 2013), 
behavioral reinforcement protocols might be best suited to shape typical behaviors that are 
reduced or absent (negative features; Koegel et al. 2009). The treatment of prominent 
negative features of ASD could also be informed and enhanced by drawing upon both 
psychosocial and medical interventions that have been validated for treating related 
symptoms in other disorders, such as anxiety, depression, and schizophrenia. Finally, 
executive functioning interventions (Kenworthy et al. 2014) may be best suited to target 
underlying cognitive impairments in ASD. Thus, describing an individual’s difficulties in 
terms of positive, negative, and cognitive features may be informative in selecting which 
treatment approaches are best suited to address their particular set of difficulties and in 
considering novel ways in which existing interventions could be applied to features for 
which they are not currently targeted. Moreover, as ASD presentation often changes with 
age and with successful treatment, tracking developmental trajectories and monitoring the 
most prominent and disabling features across time and settings along positive, negative, and 
cognitive axes may inform dynamic implementation of treatments in response to the most 
pressing features at a given point in time.
Increased research into the particular neural and genetic etiology of positive, negative, and 
cognitive features of ASD may pave the way for more precise diagnosis and targeted 
treatments. As with schizophrenia, several broad mechanisms, including an imbalance in 
excitatory and inhibitory neurotransmission and atypical neural synchrony, have been 
proposed to be at the core of ASD (Rubenstein and Merzenich 2003; Uhlhaas and Singer 
2006). However, these models do not clearly articulate why the hallmark pattern of features 
associated with ASD result from the proposed underlying neural abnormalities, while other 
signs and symptoms do not. The ability to test the likelihood of these mechanisms 
underlying ASD may benefit from more clearly articulating specific feature clusters and 
dimensions within the ASD phenotype. To date, though not previously discussed in this 
manner, specific brain regions have been associated with negative features, such as deficits 
in social perception (McPartland et al. 2011), whereas others have been associated with 
cognitive impairments (Schmitz et al. 2006), and still others have been linked to different 
positive features, including circumscribed interests (Cascio et al. 2014). While certainly 
some underlying neurobiological abnormalities may link to features that span positive, 
negative, and cognitive dimensions, exploring them along these dimensions may offer 
opportunity to identify other specific biological alterations that may map more directly onto 
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one feature dimension than another, whereas this link may have previously been obscured by 
the search for brain-behavior mappings to explain ASD features clustered within existing 
DSM domains.
Work also has identified links between known genetic risk factors for ASD and feature 
clusters. For example, in some genetic disorders that result in ASD, the phenotypic 
presentation is more homogenous across individuals and features appear to be more 
negative, such as failure to initiate conversation, than positive (Bruining et al. 2010). 
Whether specific genes map to positive versus negative versus cognitive features is yet 
unknown as we are limited by how the field has been looking for them. For example, mouse 
models of ASD are developed and evaluated based on the extent to which their phenotypic 
expression is analogous to the social, communication, and restricted/ repetitive symptoms of 
ASD (Silverman et al. 2010). If the mouse models were instead evaluated based on their 
expression of positive vs. negative features, we might find differences in genes underlying 
positive vs. negative feature expression. Likewise, underlying mechanisms may not be 
uncovered if researchers are lumping across positive and negative expressions of an attribute 
(e.g. exaggerated vs. restricted affect) in describing and attempting to identify the biological 
basis of the broader attribute (i.e., atypical facial expressions). This point is well illustrated 
in the context of mood disorders, where mania (i.e., elevated mood) and depression (i.e., low 
mood) have different biological correlates (Delvecchio et al. 2012; Kempton et al. 2011). If 
researchers had lumped the positive and negative manifestations of altered mood together as 
a single construct of “atypical mood expression,” these different mechanisms might not have 
been uncovered, and our diagnosis and treatment of affected individuals would be well 
behind where it is today. Thus, conceptualization of ASD symptomatology along positive, 
negative, and cognitive dimensions holds promise to inform and build upon existing 
neuroimaging and genetic findings attempting to parse clinical heterogeneity in biologically 
meaningful ways.
Summary
The introduction of RDoC and the revised diagnostic classification of ASD in DSM-5 call 
for a new way of conceptualizing heterogeneous ASD features. Here we have suggested a 
novel conceptualization of ASD on the basis of positive, negative, and cognitive dimensions, 
paralleling the dimensional symptom framework already recognized in schizophrenia. We 
argue that this conceptualization will provide three vital research opportunities: (1) a new 
means of capturing the heterogeneity of feature presentation in ASD, (2) more precise 
identification of common etiologies and neural abnormalities underlying feature dimensions, 
and (3) dimension-specific treatment approaches across disorders. Collectively, we posit that 
both researchers and clinicians in the ASD field would benefit substantially by leveraging 
the dimensional feature understanding that has been advanced through schizophrenia 
research. Ultimately, this cross-fertilization has the potential to improve our mechanistic 
understanding of links from genes and cells, to neural systems, and ultimately to specific 
patterns of behavioral impairments that exist within and across currently defined diagnostic 
categories.
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